George Lundberg, MD Editor in Chief at Cancer Commons

  •   George Lundberg, MD

    Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

    Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    “Patients with cancer need to be embraced with love and compassion. They need caring beyond medicine.”

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

    The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.

    Go to full paper published in Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.